Absci Investor Presentation Deck

roved, 11.2% of drugs entering clinical trials approved 2006: 22 approved, 11.2% 2007: 18 approved, 10.7% 2008: 24 approved, 6 approved, 7.8% 2010: 21 approved, 6.8% 2011: 35 approved, 6.1% 2012: 39 approved, 5.3% 2013: 27 approved, 5.2% 2014: 41 7% 2015: 45 approved, 13.8% ABSCI CORPORATION 2023 ALL RIGHTS RESERVED in DUR- OUR = Instead of finding the needle in the haystack, Absci is creating the needle ME Measurement Rate mass - OD Vol. pt ↳ Weigh 8/2-hr Boma the Specific poltivity Resus. D DBII ASI ASI 96w 19 384 w 7 The incub 384 W Į seal pla ↓ Source Spin 51 ✓ 4°C Incubat absci. 7

View entire presentation